


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of Formula (I):



wherein:

R<sub>1</sub> is H or C<sub>1-8</sub> alkyl;

R<sub>2</sub> is C<sub>2-4</sub> alkenyl, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> haloalkyl; and

R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are each independently H, C<sub>1-4</sub> acyl, C<sub>1-4</sub> acyloxy, C<sub>1-4</sub> acylthioxy, C<sub>2-4</sub> alkenyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylcarboxamido, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonamide, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> alkylthio, amino, C<sub>1-4</sub> alkylamino, carbo-C<sub>1-4</sub>-alkoxy, carboxamide, cyano, C<sub>2-6</sub> dialkylamino, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkylsulfinyl, C<sub>1-4</sub> haloalkylsulfonyl, C<sub>1-4</sub> haloalkylthio, halogen, hydroxyl, phenyl, and thiol; or

a pharmaceutically acceptable salt, hydrate and solvate thereof;

provided that the compound is not 1-(4-Chloro-phenyl)-2-methyl-piperazine; 1-(3,5-Difluoro-phenyl)-2-methyl-piperazine; 2-Methyl-1-(2-methylsulfonyl-phenyl)-piperazine; 4-Amino-3-fluoro-2-(2-methyl-piperazin-1-yl)-5-nitro-benzonitrile; 2-Methyl-1-phenyl-piperazine; 4-(2-Isopropyl-piperazin-1-yl)-2-trifluoromethyl-benzonitrile; 4-(2-Ethyl-piperazin-1-yl)-2-trifluoromethyl-benzonitrile; 4-(2-Methyl-piperazin-1-yl)-2-trifluoromethyl-benzonitrile; 1-(3-Chloro-phenyl)-2-methyl-piperazine; 2-Methyl-1-m-tolyl-piperazine; 4-(2-Methyl-piperazin-1-yl)-benzamide; 1-(2-Fluoro-

phenyl)-2-methyl-piperazine; 4-(2-Methyl-piperazin-1-yl)-phenol; 1-(3-Methoxy-phenyl)-2-methyl-piperazine; 2-Methyl-1-(3-trifluoromethyl-phenyl)-piperazine; 1-(4-Methoxy-phenyl)-2-methyl-piperazine; 2-Methyl-1-p-tolyl-piperazine; 2,4-Dimethyl-1-phenyl-piperazine; 4-Chloro-5-(4-ethyl-2-methyl-piperazin-1-yl)-benzene-1,2-diamine; 4-Chloro-5-(4-ethyl-2-methyl-piperazin-1-yl)-2-nitro-phenylamine; 5-(4-Ethyl-2-methyl-piperazin-1-yl)-2-nitro-4-trifluoromethyl-phenylamine; and 5-(4-Ethyl-2-methyl-piperazin-1-yl)-4-methyl-2-nitro-phenylamine.

2. (Original) The compound according to claim 1 wherein  $R_1$  is H.
3. (Original) The compound according to claim 1 wherein  $R_1$  is  $C_{1-8}$  alkyl.
- 4-8. (Canceled).
9. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 8 wherein  $R_2$  is  $C_{2-4}$  alkenyl.
10. (Canceled).
11. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 8 wherein  $R_2$  is  $C_{1-4}$  alkyl.
12. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 8 wherein  $R_2$  is methyl.
- 13-16. (Canceled).
17. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 16 wherein  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$  and  $R_7$  are each independently selected from the group consisting of H,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkyl, cyano,  $C_{1-4}$  haloalkoxy,  $C_{1-4}$  haloalkyl and halogen.

18. (Canceled).

19. (Original) The compound according to claim 17 wherein R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are each independently selected from the group consisting of H, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> haloalkyl and halogen.

20. (Original) The compound according to claim 17 wherein R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are each independently selected from the group consisting of H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, cyano, OCF<sub>3</sub>, CF<sub>3</sub>, F, Cl and Br.

21. (Original) The compound according to claim 17 wherein R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are each independently selected from the group consisting of H, CF<sub>3</sub>, F, Cl and Br.

22. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 16 wherein R<sub>3</sub> is H or F.

23. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 16 and 22 wherein R<sub>4</sub> is selected from the group consisting of H, cyano, F, Cl and Br.

24. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 16, 22 and 23 wherein R<sub>5</sub> is selected from the group consisting of H, CH<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, OCF<sub>3</sub>, CF<sub>3</sub>, F, Cl and Br.

25. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 16 and 22 to 24 wherein R<sub>6</sub> is selected from the group consisting of H, F, Cl and Br.

26. (Currently amended) The compound according to ~~any one of claims~~ claim 1 to 16 and 22 to 25 wherein R<sub>7</sub> is selected from the group consisting of H, CH<sub>3</sub>, F, Cl and Br.

27. (Original) The compound of claim 1 selected from the group consisting of:  
1-(2,3-Difluoro-phenyl)-2-ethyl-piperazine;

1-(3-Fluoro-phenyl)-2-ethyl-piperazine;  
1-(4-Fluoro-phenyl)-2-ethyl-piperazine;  
(R)-1-(3-Chloro-4-fluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(3-Chloro-4-fluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(3,4-Difluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(3,4-Difluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(3-Chloro-2-fluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(3-Chloro-2-fluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(4-Fluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(4-Fluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(3,4-Dichloro-phenyl)-2-methyl-piperazine;  
(S)-1-(3,4-Dichloro-phenyl)-2-methyl-piperazine;  
(R)-1-(3-Chloro-4-methyl-phenyl)-2-methyl-piperazine;  
(S)-1-(3-Chloro-4-methyl-phenyl)-2-methyl-piperazine;  
(R)-1-(3,4-Difluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(3,4-Difluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(3,5-Dichloro-phenyl)-2-methyl-piperazine;  
(S)-1-(3,5-Dichloro-phenyl)-2-methyl-piperazine;  
(R)-1-(2,5-Difluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(2,5-Difluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(4-Chloro-3-fluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(4-Chloro-3-fluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(3-Chloro-2-methyl-phenyl)-2-methyl-piperazine;  
(S)-1-(3-Chloro-2-methyl-phenyl)-2-methyl-piperazine;  
(R)-1-(5-Chloro-2-fluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(5-Chloro-2-fluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(5-Chloro-2-methyl-phenyl)-2-methyl-piperazine;  
(S)-1-(5-Chloro-2-methyl-phenyl)-2-methyl-piperazine;  
1-(3-Chloro-4-fluoro-phenyl)-2-ethyl-piperazine;  
1-(3-Chloro-phenyl)-2-ethyl-piperazine;  
1-(4-Chloro-phenyl)-2-ethyl-piperazine;

1-(3,4-Difluoro-phenyl)-2-ethyl-piperazine and  
(R)-1-(5-Chloro-2-fluoro-phenyl)-2-ethyl-piperazine;  
or a pharmaceutically acceptable salt, hydrate and solvate thereof.

28. (Original) The compound of claim 1 selected from the group consisting of:

(R)-1-(2-Fluoro-5-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(S)-1-(2-Fluoro-5-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(R)-1-(4-Chloro-2-fluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(4-Chloro-2-fluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(3-Chloro-5-fluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(3-Chloro-5-fluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(3-Fluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(3-Fluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(2-Fluoro-4-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(S)-1-(2-Fluoro-4-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(R)-1-(2-Chloro-3-fluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(2-Chloro-3-fluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(2-Fluoro-5-methyl-phenyl)-2-methyl-piperazine;  
(S)-1-(2-Fluoro-5-methyl-phenyl)-2-methyl-piperazine;  
(R)-1-(4-Fluoro-biphenyl-3-yl)-2-methyl-piperazine;  
(S)-1-(4-Fluoro-biphenyl-3-yl)-2-methyl-piperazine;  
(R)-1-(2,5-Difluoro-4-methoxy-phenyl)-2-methyl-piperazine;  
(S)-1-(2,5-Difluoro-4-methoxy-phenyl)-2-methyl-piperazine;  
(R)-1-(2-Fluoro-4-methyl-phenyl)-2-methyl-piperazine;  
(S)-1-(2-Fluoro-4-methyl-phenyl)-2-methyl-piperazine;  
(R)-1-(2-Chloro-5-fluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(2-Chloro-5-fluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(2-Chloro-4-fluoro-phenyl)-2-methyl-piperazine;  
(S)-1-(2-Chloro-4-fluoro-phenyl)-2-methyl-piperazine;  
(R)-1-(2,4-Dichloro-phenyl)-2-methyl-piperazine;  
(S)-1-(2,4-Dichloro-phenyl)-2-methyl-piperazine;

(R)-1-(2,5-Dichloro-phenyl)-2-methyl-piperazine;  
(S)-1-(2,5-Dichloro-phenyl)-2-methyl-piperazine;  
(R)-1-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(S)-1-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(R)-1-(4-Fluoro-2-methyl-phenyl)-2-methyl-piperazine;  
(S)-1-(4-Fluoro-2-methyl-phenyl)-2-methyl-piperazine;  
(R)-1-(2-Chloro-phenyl)-2-methyl-piperazine;  
(S)-1-(2-Chloro-phenyl)-2-methyl-piperazine;  
(R)-1-(2,3-Dichloro-phenyl)-2-methyl-piperazine;  
(R)-1-(2,3-Dichloro-phenyl)-2-methyl-piperazine;  
(R)-1-(2,6-Dichloro-phenyl)-2-methyl-piperazine;  
(R)-1-(2,6-Dichloro-phenyl)-2-methyl-piperazine;  
(R)-1-(2-Chloro-5-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(R)-1-(2-Chloro-5-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(R)-2-Methyl-1-(4-trifluoromethyl-phenyl)-piperazine;  
(S)-2-Methyl-1-(4-trifluoromethyl-phenyl)-piperazine;  
(R)-1-(2-Fluoro-3-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(S)-1-(2-Fluoro-3-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(R)-1-(3-Fluoro-5-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(R)-1-(3-Fluoro-5-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(R)-1-(4-Chloro-3-trifluoromethyl-phenyl)-2-methyl-piperazine;  
(S)-1-(4-Chloro-3-trifluoromethyl-phenyl)-2-methyl-piperazine; and  
(R)-2,4-Dimethyl-1-(3-trifluoromethyl-phenyl)-piperazine;  
or a pharmaceutically acceptable salt, hydrate and solvate thereof.

29. (Original) The compound of claim 1 selected from the group consisting of:


1-(2-Bromo-phenyl)-2-vinyl-piperazine;  
1-(4-Chloro-phenyl)-2-vinyl-piperazine;  
1-(3-Fluoro-phenyl)-2-vinyl-piperazine;  
1-(3-Chloro-4-fluoro-phenyl)-2-vinyl-piperazine;  
1-(3-Chloro-phenyl)-2-vinyl-piperazine;

1-(3-Bromo-phenyl)-2-vinyl-piperazine;  
1-(3,5-Dichloro-phenyl)-2-vinyl-piperazine;  
1-(2-Bromo-4-isopropyl-phenyl)-2-vinyl-piperazine;  
1-(2-Bromo-4-trifluoromethoxy-phenyl)-2-vinyl-piperazine;  
1-(2-Bromo-4-trifluoromethyl-phenyl)-2-vinyl-piperazine;  
3-(2-Vinyl-piperazin-1-yl)-benzonitrile;  
1-(3,5-Difluoro-phenyl)-2-vinyl-piperazine;  
1-*o*-Tolyl-2-vinyl-piperazine and  
1-(2,3-Difluoro-phenyl)-2-vinyl-piperazine;  
or a pharmaceutically acceptable salt, hydrate and solvate thereof.

30. (Currently amended) The compound according to ~~any one of claims claim 1 to 26~~ wherein said compound is an *R* enantiomer.

31. (Currently amended) The compound according to ~~any one of claims claim 1 to 26~~ wherein said compound is an *S* enantiomer.

32. (Original) A pharmaceutical composition comprising a pharmaceutical acceptable carrier in combination with at least one compound according to Formula (I):



wherein:

R<sub>1</sub> is H or C<sub>1-8</sub> alkyl;

R<sub>2</sub> is C<sub>2-4</sub> alkenyl, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> haloalkyl; and

R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are each independently H, C<sub>1-4</sub> acyl, C<sub>1-4</sub> acyloxy, C<sub>1-4</sub> acylthioxy, C<sub>2-4</sub> alkenyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylcarboxamido, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonamide, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> alkylthio, amino, C<sub>1-4</sub> alkylamino, carbo-

C<sub>1-4</sub>-alkoxy, carboxamide, cyano, C<sub>2-6</sub> dialkylamino, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkylsulfinyl, C<sub>1-4</sub> haloalkylsulfonyl, C<sub>1-4</sub> haloalkylthio, halogen, hydroxyl, phenyl, and thiol; or  
a pharmaceutically acceptable salt, hydrate and solvate thereof.

33. (Currently amended) A method of modulating a 5HT<sub>2C</sub> receptor comprising contacting said receptor with a therapeutically effective amount of a compound as in ~~any one of claims claim~~ 1 to 31.

34. (Original) The method according to claim 33 wherein said compound is an agonist of said receptor.

35. (Currently amended) A method of prophylaxis or treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus or sleep apnea comprising administering to an individual in need of such prophylaxis or treatment a therapeutically effective amount of a compound according to ~~any one of claims claim~~ 1 to 31 or a pharmaceutical composition according to claim 32.

36. (Original) The method according to claim 35 wherein the disorders of the central nervous system are selected the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, Alzheimer disease, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

37. (Original) The method according to claim 36 wherein the disorder of the central nervous system is obesity.



38. (Canceled).

39. (Original) The method according to claim 36 wherein the sexual dysfunction is Male erectile dysfunction.

40-44. (Canceled).

45. (Currently amended) The method according to claim ~~44~~ 37 or 39 wherein said ~~mammal~~ individual is a human.

46. (Currently amended) A method of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount of a compound according to ~~any one of claims claim 1 to 31~~ or a pharmaceutical composition according to claim 32.

47. (Canceled).

48. (Currently amended) The method according to claim ~~47~~ 46 wherein said ~~mammal~~ individual is a human.

49. (Currently amended) A method of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound according to ~~any one of claims claim 1 to 31~~ or a pharmaceutical composition according to claim 32.

50. (Canceled).

51. (Currently amended) The method according to claim ~~50~~ 49 wherein said ~~mammal~~ individual is a human.

52. (Currently amended) A method of controlling weight gain of an individual comprising administering to said individual suffering from weight control a therapeutically effective amount

of a compound according to ~~any one of claims claim 1 to 31~~ or a pharmaceutical composition according to claim 32.

53. (Canceled).

54. (Currently amended) The method according to claim ~~53~~ 52 wherein said ~~mammal~~ individual is a human.

55-58. (Canceled).

59. (Currently amended) A method of producing a pharmaceutical composition comprising admixing at least one compound according to ~~any one of claims claim 1 to 31~~ and a pharmaceutically acceptable carrier.

60-78. (Canceled).

79. (New) The compound according to claim 1 wherein:  
R<sub>1</sub> is H, methyl, ethyl, *n*-propyl, *iso*-propyl or *n*-butyl;  
R<sub>2</sub> is a vinyl, methyl, ethyl, *n*-propyl, C<sub>1-4</sub> haloalkyl or -CF<sub>3</sub>;  
R<sub>3</sub> is H or F;  
R<sub>4</sub> is selected from the group consisting of H, cyano, F, Cl and Br;  
R<sub>5</sub> is selected from the group consisting of H, CH<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, OCF<sub>3</sub>, CF<sub>3</sub>, F, Cl and Br;  
R<sub>6</sub> is selected from the group consisting of H, F, Cl and Br; and  
R<sub>7</sub> is selected from the group consisting of H, CH<sub>3</sub>, F, Cl and Br.

80. (New) A method of treating a 5HT<sub>2C</sub> receptor associated disorder comprising administering to an individual in need of such treatment an effective amount of a compound according to claim 1, or a pharmaceutical composition according to claim 32.